Protalix BioTherapeutics ... (PLX)
AMEX: PLX
· Real-Time Price · USD
1.48
-0.04 (-2.63%)
At close: Aug 15, 2025, 3:59 PM
1.50
1.35%
After-hours: Aug 15, 2025, 05:59 PM EDT
Protalix BioTherapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.62M | 6.49M | 3.24M | -2.2M | -4.59M | -6.04M | -1.85M | 19.34M | -3.13M | -3.74M | -3.57M | -5.33M | -2.29M | -6.67M | -4.2M | -11.24M | -5.47M |
Depreciation & Amortization | 346K | 334K | 329K | 319K | 322K | 313K | 305K | 293K | 280K | 275K | 273K | 268K | 270K | 259K | 285K | 288K | 286K |
Stock-Based Compensation | 540K | 654K | 620K | 998K | 981K | 1.37M | 1.1M | 438K | 546K | 539K | 422K | 288K | 836K | 418K | 563K | 578K | 816K |
Other Working Capital | -18K | -17K | -16.96M | 1.66M | 11.05M | 1K | 9K | -11.8M | -1.38M | 2.85M | -2.93M | -1K | -2.65M | -715K | 1.68M | 15.96M | -3.67M |
Other Non-Cash Items | -372K | -44K | 5.41M | -503K | -466K | -2.91M | -407K | -414K | 9K | 15K | -5K | -1.2M | -38K | 403K | 880K | 1.03M | 777K |
Deferred Income Tax | -113K | n/a | 443K | -69K | -138K | 3.09M | 38K | -3.14M | n/a | n/a | n/a | n/a | n/a | 8K | 842K | -14K | -23K |
Change in Working Capital | -1.84M | -3.45M | -5.93M | -2.15M | 8.08M | 7.77M | -6.07M | -11.54M | -702K | 300K | -6.33M | -1.38M | -4.61M | 492K | -251K | 15.88M | -6.21M |
Operating Cash Flow | -5.06M | 3.99M | 4.11M | -3.61M | 4.19M | 3.6M | -6.89M | 4.97M | -3M | -2.61M | -9.2M | -7.36M | -5.83M | -5.09M | -1.88M | 6.52M | -9.83M |
Capital Expenditures | -306K | -425K | -87K | -172K | -598K | -250K | -447K | -204K | -248K | -213K | -58K | -128K | -229K | -448K | -344K | -281K | -386K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -37.84M | n/a | n/a | 53K |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 16M | n/a | n/a | -16M | 37.84M | n/a | n/a | -37.84M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 5M | 5M | 6M | n/a | n/a | 37.84M | 5M | 7.5M | 7.5M |
Other Investing Acitivies | -6K | -14.89M | 20.41M | -8K | -8K | -92K | -20.43M | -18K | -20K | -15.83M | -30K | 485K | -28K | 49K | -27K | 321K | -16K |
Investing Cash Flow | -312K | -15.32M | 20.33M | -180K | -606K | -342K | -20.88M | -222K | 4.73M | 4.95M | 5.91M | 357K | -16.26M | 37.44M | 4.63M | 7.54M | -30.68M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 40K | -25.99M | n/a | -4.09M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2.21M | n/a | -20.42M | n/a | n/a | n/a | n/a | 712K | n/a | n/a | n/a | 2.64M | n/a | -4.09M | n/a | n/a | 46.2M |
Financial Cash Flow | 5.08M | 3.63M | -20.42M | n/a | n/a | n/a | n/a | 10.43M | 14.23M | 4.08M | 1.52M | 2.64M | n/a | -4.05M | -25.99M | n/a | 42.11M |
Net Cash Flow | -302K | -7.65M | 4.01M | -3.81M | 3.58M | 3.23M | -27.78M | 15.15M | 15.93M | 6.39M | -1.77M | -4.4M | -22.1M | 28.34M | -23.24M | 14.05M | 1.56M |
Free Cash Flow | -5.36M | 3.57M | 4.02M | -3.78M | 3.59M | 3.35M | -7.33M | 4.77M | -3.25M | -2.82M | -9.26M | -7.48M | -6.06M | -5.54M | -2.22M | 6.24M | -10.22M |